Nonalcoholic steatohepatitis (NASH) drugs market

被引：54
|
作者：
Cassidy, Sorcha [1 ]
Syed, Basharut A. [1 ]
机构：
[1] PSL Grp, FirstWord Pharma, 75 Davies St, London W1K 5JN, England
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 11期
关键词：
D O I：
10.1038/nrd.2016.188
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease, is predicted to become the leading reason for liver transplantation by 2020. This analysis provides an overview of emerging therapies for NASH.
引用
收藏
页码：745 / 746
页数：2
相关论文
共 50 条
  • [41] Gallstones associated with nonalcoholic steatohepatitis (NASH) and metabolic syndrome
    Yener, Oktay
    Aksoy, Fikret
    Demir, Mustafa
    Ozcelik, Alp
    Erengul, Canan
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2010, 21 (04): : 411 - 415
  • [42] Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
    Fiorucci, Stefano
    Biagioli, Michele
    Sepe, Valentina
    Zampella, Angela
    Distrutti, Eleonora
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (06) : 623 - 632
  • [43] Predictors of nonalcoholic steatohepatitis in Japanese patients: Thioredoxin and NASH
    Okanoue, T
    Yamauchi, N
    Furutani, M
    Hirohama, A
    Sumida, Y
    Nakashima, T
    NASH AND NUTRITIONAL THERAPY, 2005, : 64 - 72
  • [44] Lipohepatotoxicity and Nonalcoholic Steatohepatitis (NASH)-Like Metabolic Disorders
    Cherkaoui-Malki, Mustapha
    CURRENT DRUG METABOLISM, 2012, 13 (10) : 1357 - 1357
  • [45] Genetic background of Japanese patients with nonalcoholic steatohepatitis (NASH)
    Saibara, T
    Namikawa, C
    Zhang, SP
    Ma, RH
    Nozaki, Y
    Nemoto, Y
    Ono, M
    Akisawa, N
    Iwasaki, S
    Hiroi, M
    Enzan, H
    Onishi, S
    NASH AND NUTRITIONAL THERAPY, 2005, : 58 - 63
  • [46] Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)
    Ure, Daren R.
    Trepanier, Daniel J.
    Mayo, Patrick R.
    Foster, Robert T.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 163 - 178
  • [47] Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
    Wattacheril, Julia
    Issa, Danny
    Sanyal, Arun
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58, 2018, 58 : 649 - 662
  • [48] ROLE OF AUTOPHAGY IN HEPATOCYTE DEATH IN NONALCOHOLIC STEATOHEPATITIS (NASH)
    Lavallard, Vanessa
    Bonnafous, Stephanie
    Rousseau, Deborah
    Anty, Rodolphe
    Saint-Paul, Marie-Christine M.
    Iannelli, Antonio
    Deveaux, Vanessa
    Lotersztajn, Sophie
    Gounon, Pierre
    Gugenheim, Jean
    Brustel, Yannick Le Marchand
    Tran, Albert
    Gual, Philippe
    HEPATOLOGY, 2010, 52 (04) : 1050A - 1051A
  • [49] Thiazolidinediones and Nonalcoholic Steatohepatitis (NASH): A Meta-analysis
    Muthiah, KaruppanChetty
    Kelley, Melissa
    Fardy, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S97 - S97
  • [50] Efficacy and safety of drugs for nonalcoholic steatohepatitis
    Shen, Bo
    Lu, Lun Gen
    JOURNAL OF DIGESTIVE DISEASES, 2021, 22 (02) : 72 - 82
12345